BETHLEHEM, Pa., May 11, 2016 /PRNewswire-USNewswire/ -- Cernostics, Inc. today announced that findings from three scientific studies of its new TissueCypher® Barrett’s Esophagus Assay will be presented at the Digestive Disease Week (DDW) meeting in San Diego. DDW is the world’s largest conference on Gastro-intestinal Medicine and the ideal place for physicians to view data supporting the reliability and cost-effectiveness of Cernostics’ TissueCypher® Assay for Barrett’s Esophagusthe first clinical assay of its kind to predict the risk of developing esophageal cancer.
“We are delighted that DDW has recognized the significance of the clinical data supporting our TissueCypher® Barrett’s Assay,” commented Mike Hoerres, Cernostics, Inc. CEO.
“And Gastroenterologists will be pleased to learn that the test identifies high risk patients that are 9x more likely to progress to high grade dysplasia or cancer within five years of biopsy, providing a new tool to improve clinical decision making,” he added.
DDW attendees are invited to visit Cernostics at Exhibit Booth #551, or attend the scientific presentations listed below:
A Novel Tissue Systems Pathology Test Predicts Progression in Barrett’s Esophagus Patients
Session Type: Podium Presentation #301
Session Title: Barrett’s Esophagus: Diagnosis, Management and Surveillance
Date: May 22, 2016 Time: 10:45 - 11:00 a.m. Location: SDCC Rm 10
A Tissue Systems Pathology Test Detects a Field Effect Associated With High Grade Dysplasia and Esophageal Cancer in Barrett’s Esophagus Patients
Session Type: Poster Session
Session Title: Barrett’s Esophagus: Diagnosis, Management and Surveillance (Sa1257)
Date: May 21, 2016 Time: Noon - 2:00 p.m. Location: Hall C
A Cost-Effectiveness Analysis of a Cancer Risk Prediction Test for Patients with Barrett’s Esophagus
Session Type: Poster Session
Session Title: Barrett’s Esophagus: Diagnosis, Management and Surveillance (Sa1261)
Date: May 21, 2016 Time: Noon - 2:00 p.m. Location: Hall C
PLEASE NOTE: Scientific colleagues from Geisinger will be making the following presentation at the ISPOR meeting (International Society for Pharmacoeconomics & Outcomes Research) in Washington, DC on May 23.
A Cost-Effectiveness Analysis of a Test That Predicts Risk of Malignant Progression in Barrett’s Esophagus
Session Type: Podium Presentation Session II (CN4)
Session Title: Cancer OutcomesStudies
Date: May 23, 2016 Time: 3:45 pm- 4:45 p.m.
For additional information please visit www.cernostics.com
Contact: Josh Weinstein
jwEinstein Strategic Messaging, Inc.
610-438-8853 jw@jweinstein.guru
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cernostics-announces-scientific-presentations-at-ddw-and-ispor-meetings-demonstrating-clinical-validation-and-cost-effectiveness-of-new-tissuecypher-barretts-esophagus-assay-300266468.html
SOURCE Cernostics, Inc.
